Furazolidon tablets 0.05 №20


Manufacturer: Ukraine

It is used for the treatment of patients with diseases of the digestive and urinary systems, such as: dysentery; paratyphoid; enterocolitis; giardiasis; food intoxication.



Furazolidon Storage
active substance: furazolidone;

1 tablet contains furazolidone 0.05 g (50 mg);

excipients: potato starch; lactose monohydrate; colloidal anhydrous silica; calcium stearate.

Furazolidon Dosage form

Basic physical and chemical properties: tablets of yellow or greenish-yellow color, with a flat surface and a facet.

Furazolidon Pharmacotherapeutic group
Antimicrobial and antiseptic agents. Furazolidone. ATX code G01A X06.

Pharmacological properties


Furazolidone is an antimicrobial and antiprotozoal agent derived from nitrofuran. Disrupts the process of bacterial cellular respiration, inhibits the biosynthesis of nucleic acids. Depending on the concentration has a bacteriostatic or bactericidal effect. Active against gram-negative rods (Escherichia, Salmonella, Shigella, Proteus, Klebsiella, Citrobacter), gram-positive cocci (streptococci, staphylococci), protozoa (Giardia, Trichomonas). Among the causative agents of intestinal infections, the most sensitive are the causative agents of dysentery, typhoid fever and paratyphoid fever. Weakly affects the causative agents of purulent and anaerobic infections. Resistance to furazolidone develops slowly. Activates phagocytosis, does not suppress the immune system.


When taken orally, it is rapidly absorbed in the gastrointestinal tract and distributed to tissues, including the central nervous system. Therapeutic concentration in the blood is maintained for 4-6 hours. It does not create high concentrations in blood and tissues (including kidneys), because it is largely rapidly metabolized in the liver, becoming an amino derivative. The main route of elimination is renal excretion (65%). Partially excreted in the bile, reaching high concentrations in the intestinal lumen, which allows its use in intestinal infections. In renal failure, the drug accumulates in the blood due to slow excretion.

Bacillary dysentery, paratyphoid, food poisoning, enterocolitis, giardiasis, Trichomonas colpitis.

Terminal stage of chronic renal failure, liver dysfunction, glucose-6-phosphate dehydrogenase deficiency, hypersensitivity to any components of the drug and nitrofurans.

Interaction with other medicinal products and other forms of interaction
Concomitant use of furazolidone with monoamine oxidase inhibitors, sympathomimetics, tricyclic antidepressants and foods containing tyramine, there is a risk of hypertensive crisis. When combined with chloramphenicol and ristomycin increases the risk of hematopoiesis.

Toxic psychosis may occur with concomitant use of furazolidone with amitriptyline.

Aminoglycosides and tetracycline enhance the antimicrobial effect of furazolidone.